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INTRODUCTION
Primary liver cancer is one of the world's deadliest cancers and the third most common cause of cancer death. Hepatocellular carcinoma (HCC) represents 85%-90% of primary liver cancers and is refractory to nearly all currently available anti-cancer therapies. Over the last 20 years, the incidence of HCC in developed countries has been increasing, doubling in the United States (Font-Burgada et al., 2016) . The obesity epidemic and the accompanying development of non-alcoholic fatty liver disease (NALFD), evident in >85% of all obese individuals, are thought to be key contributors to the development of HCC (Younes and Bugianesi, 2018) . Indeed, obesity, the metabolic syndrome, and NAFLD account for 30%-40% of the increase in HCC in developed countries, and the risk of mortality from HCC in men with a body mass index (BMI) of 35-40 kg/m 2 is 4.5-fold times greater than in patients with normal body weight (Calle et al., 2003) .
NAFLD has an estimated worldwide prevalence of 25.2% (Younossi et al., 2016) and encompasses a broad spectrum of liver conditions ranging from simple steatosis, or non-alcoholic fatty liver (NAFL), to the more severe and progressive disease, non-alcoholic steatohepatitis (NASH). NASH is characterized by overt hepatic inflammation and tissue damage and ensuing reparative responses that result in fibrosis and ultimately cirrhosis, the principal cause of liver-related morbidity and mortality (Font-Burgada et al., 2016) . Obesity-associated NASH is currently the third leading cause for liver transplantation and is expected to surpass hepatitis C as the principal cause for liver transplantation in the developed world (Shaker et al., 2014) .
The mechanisms that underpin the progression from NAFL to NASH are complex and involve multiple insults and contributions from genetic modifiers that influence disease severity and progression (Font-Burgada et al., 2016) . Lipotoxicity and oxidative stress are considered central to the transition to NASH and fibrosis (Font-Burgada et al., 2016) . Several processes produce reactive oxygen species (ROS), including hepatic anaplerotic/cataplerotic reactions heightened in obesity, fatty acid oxidation, endoplasmic reticulum (ER) stress, inflammation, and the induction of ROS-producing NAD(P)H oxidases (Anderson et al., 2009; Bettaieb et al., 2015; Nakagawa et al., 2014; Perry et al., 2015; Satapati et al., 2015; Xu et al., 2005) . Such oxidative stress is thought to promote hepatocyte cell death and the ensuing inflammatory and reparative responses that lead to fibrosis and if unresolved, cirrhosis (Font-Burgada et al., 2016; Ringelhan et al., 2018) . ROS have been detected in liver biopsies from patients with chronic hepatitis (Tanaka et al., 2008) and in the liver parenchyma in rodent models of obesity Park et al., 2010) . Moreover, genetic studies in mice provide evidence for the increased ROS contributing to NASH and the genesis of liver cancer (Elchuri et al., 2005; Luedde et al., 2007; Neumann et al., 2003) . In rodents, drugs that attenuate ROS production prevent NASH (Perry et al., 2015) . At least one mechanism by which ROS may drive disease progression is through the induction of protein tyrosine kinase (PTK) signaling by oxidizing and inactivating protein tyrosine phosphatases (PTPs) (Tiganis, 2011) . Our previous studies have shown that hepatic PTPs can be extensively oxidized in the livers of obese mice with NAFL , but the extent to which this might be pertinent to NASH remains unknown.
A key feature of NASH is the activation of resident immune cells, in particular Kupffer cells, and the recruitment of macrophages, B cells, natural killer (NK) cells, and CD4 + and CD8 + T cells that contribute to the inflammation and the persistent cycle of tissue damage and repair (Font-Burgada et al., 2016; Ringelhan et al., 2018) . The importance of liver inflammatory macrophages is underscored by studies showing that tumor necrosis factor (TNF) from macrophages is essential for NASH and fibrosis in MUP-Upa mice that exhibit increased steatosis and progress to NASH and fibrosis and HCC when fed a high-fat obesity-promoting diet (Nakagawa et al., 2014) . The importance of infiltrating T cells is illustrated by the reliance on antigen presentation via MHC class I and the recruitment of activated CD8 + T cells for the development of NASH and pericellular fibrosis in mice fed a choline-deficient high fat diet (Wolf et al., 2014) . The molecular mechanisms driving the recruitment and activation of immune cells contributing to NASH pathogenesis have remained unresolved.
HCC can develop in a subset of obese NASH patients, but the precise mechanisms that give rise to HCC in some NASH patients and not others remain unresolved (Font-Burgada et al., 2016) . Moreover, while HCC is typically accompanied by cirrhosis or severe fibrosis (Font-Burgada et al., 2016) , there are a growing number of NAFLD patients without cirrhosis or advanced fibrosis that develop HCC (Alexander et al., 2013; Baffy et al., 2012; Mittal et al., 2015; Paradis et al., 2009; Rahman et al., 2013; Takuma and Nouso, 2010; Younes and Bugianesi, 2018) . How HCC develops under these disparate conditions remains unclear. Over 28,000 somatic mutations have been identified in HCC (Schulze et al., 2015) . These mutations influence the activation of tumor-promoting signaling pathways, including interleukin (IL)-6 and/or Janus-activated kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathways (Schulze et al., 2015) . STAT-3 signaling is particularly important in driving the transformation of tumor progenitors and the development of HCC in rodents (He et al., , 2013 Naugler et al., 2007; Park et al., 2010) . Furthermore, STAT-3 is activated in the majority of human HCCs, positively correlating with tumor aggressiveness and negatively correlating with prognosis (Calvisi et al., 2006; He et al., 2010) .
We report that the inactivation of negative regulators of STAT-1 and STAT-3 signaling in obesity can drive the development of NASH and HCC. The oxidation and inactivation of the STAT-1 and STAT-3 phosphatase TCPTP and heightened STAT-1 and STAT-3 signaling were evident in NASH in both obese mice and humans. While heightened STAT-1 signaling was responsible for the recruitment of activated cytotoxic T cells and the ensuing NASH and fibrosis, this was not essential for HCC. Rather, TCPTP inactivation promoted HCC in obesity via STAT-3, independent of T cell recruitment and NASH and fibrosis. Our results shed light on mechanisms that may underpin the growing incidence of HCC in non-cirrhotic livers in the setting of NAFLD.
RESULTS

PTP Oxidation in NAFLD
Our previous studies have established that PTPs can be extensively oxidized in the livers of high-fat-fed mice that develop NAFL but not NASH . The extent to which PTP oxidation may be evident and contribute to the progression to NASH in obesity and the development of HCC remains unknown. To assess hepatic PTP oxidation in NASH we fed C57BL/6 mice (1) a standard chow diet (4% fat) that does not promote obesity, NAFL, or NASH, (2) a high fat (23% fat) diet (HFD) that promotes obesity, insulin resistance and NAFL, but not NASH, or (3) a choline-deficient high fat diet (CD-HFD; 23.5% fat) that promotes obesity, insulin resistance, and the progression from NAFL to NASH (Wolf et al., 2014) . To monitor the oxidation status of PTPs, we took advantage of a monoclonal antibody (PTPox) that was raised against a PTP1B signature motif peptide with the catalytic Cys oxidized to the irreversible sulfonic acid. This antibody can detect virtually all tyrosinespecific PTPs when oxidized to the sulfonic state (Karisch et al., 2011) . To monitor the extent of PTP oxidation in NASH, Figure 1 . Increased Hepatic PTP Oxidation and Elevated STAT Signaling in NAFL and/or NASH (A) 8-week-old male C57BL/6 mice were fed a chow diet, an HFD, or a CD-HFD for 20 weeks. Livers from individual mice were processed for immunoblot analysis for total PTP oxidation. (B) Liver core biopsies from individual obese humans with no steatosis (NAS = 0) or with NAFLD (NAS 2-4) were processed for immunoblot analysis for total PTP oxidation. (C) Murine liver extracts immunoblotted for STAT-1 Y701 (p-STAT-1), STAT-3 Y705 (p-STAT-3), or STAT-5 Y694 (p-STAT-5) phosphorylation. (D) Human livers biopsies processed for immunoblotting. Results are representative of at least three independent experiments. See also Figure S1 . C57BL/6 mice were administered a chow diet versus an HFD or CD-HFD for 20 weeks ( Figure 1A ). Livers were homogenized in an anaerobic chamber and processed for analysis by PTPox immunoblotting. As noted previously , the oxidation of several PTPs was increased in the livers of mice fed an HFD ( Figure 1A ). As seen previously , PTPox species exhibiting increased oxidation in NAFL included those co-migrating with PTP1B and TCPTP ( Figure 1A) . Importantly, we found that the oxidation status of such PTPs was evident and/or increased further in mice fed a CD-HFD (Figure 1A) that became obese (Figures S1A and S1B) and developed NASH and fibrosis ( Figure S1C ). To explore the extent to which PTP oxidation may occur in humans with NAFLD we processed liver core needle biopsies from obese patients (BMI >35) with no steatosis (NAFLD activity score [NAS] 0) versus those with NAFLD (NAS 2-4) ( Table S1 ). We found that the oxidation of several PTPs including those co-migrating with PTP1B and TCPTP was increased in the livers of patients with NAFLD versus those with no steatosis ( Figure 1B) . These findings establish the potential for hepatic PTPs to be oxidized in vivo in mice and humans in the context of NAFL and NASH and raise the possibility that such oxidation may contribute to the progressive development of NAFLD.
STAT-1 and STAT-3 Activation in NASH PTP1B and TCPTP are key negative regulators of JAK/STAT signaling. PTP1B dephosphorylates JAK-2 and Tyk-2 whereas TCPTP dephosphorylates JAK-1 and JAK-3 (Tiganis and Ben nett, 2007) . TCPTP additionally dephosphorylates STAT family members, including STAT-1, -3, and -5 in the nucleus (Loh et al., 2011; ten Hoeve et al., 2002; Wiede et al., 2017) . Accordingly, the oxidation and inactivation of PTP1B and TCPTP in obesity and NAFLD might be expected to promote STAT-1, STAT-3, and STAT-5 signaling. We found that basal STAT-1 Y701 phosphorylation (p-STAT-1) and STAT-3 Y705 phosphorylation (p-STAT-3) were increased in the livers of mice that had been fed an HFD for 20 weeks to promote obesity and NAFL but not NASH, and increased yet further in mice had been fed a CD-HFD for 20 weeks to promote obesity and the progression from NAFL to NASH ( Figure 1C ). By contrast, basal STAT5 Y694 phosphorylation was not overtly increased in the livers of mice fed an HFD or a CD-HFD for 20 weeks ( Figure 1C ). Accordingly, we hereon focused our attention on STAT-1 and STAT-3. As in mice, we found that p-STAT-1 and p-STAT-3 were also increased in the livers of obese patients (BMI >35) with NAFLD (NAS 2-4) (Table S1 ) versus those from non-obese patients (Figure 1D) . Thus, the inactivation of hepatic JAK/STAT PTPs in obese mice and humans with NAFLD and/or NASH is accompanied by increased STAT-1 and STAT-3 signaling.
TCPTP Inactivation Promotes NASH and Fibrosis in Obesity
As TCPTP (Loh et al., 2011; ten Hoeve et al., 2002) but not PTP1B can directly dephosphorylate STAT-1 and -3 in the nucleus, and TCPTP was increasingly oxidized in the livers of obese mice with NASH versus NAFL ( Figure 1A ), we focused on TCPTP and assessed the impact of deleting TCPTP in the hepatocytes (Alb-Cre;Ptpn2 fl/fl ) of C57BL/6 mice fed an HFD for up to 40 weeks. We have reported previously that juvenile 5-to 6-week-old Alb-Cre;Ptpn2 fl/fl mice fed an HFD for 12 weeks exhibit increased adiposity, hepatic steatosis, and insulin resistance . This was attributed to perturbations in the growth hormone (GH)-insulin-like growth factor (IGF)-1 pituitary axis, as a consequence of increased insulin-induced and p-STAT-5-mediated Igf-1 expression in the liver and the suppression of GH release from the pituitary . By contrast, high-fat feeding adult male Ptpn2 fl/fl versus Alb-Cre;Ptpn2 fl/fl mice from 10-12 weeks of age for periods of up to 40 weeks did not lead to changes in body weight or adiposity ( Figures S2A and S2B ), nor overt alterations in STAT-5 signaling ( Figure S2C ) or Igf-1 expression in the livers of 4-hr fasted mice ( Figure S2D ). This discordance in age-related phenotypes is in keeping with the increased levels of IGF-1 and GH that occur in early development and their ability to influence body weight primarily during pubertal adolescence (Berryman et al., 2008; Lichanska and Waters, 2008) . Importantly, high-fat feeding adult male Alb-Cre;Ptpn2 fl/fl mice for 40 weeks did not alter hepatic steatosis, as monitored by histology ( Figure S2E ), and the expression of fatty acid uptake/synthesis and lipogenesis genes (Figures S2F and S2G) . Consistent with unaltered steatosis, triacylglycerol (TAG), diacylglycerol (DAG), and ceramide levels were unaltered in the livers of 20-week high-fat-fed Alb-Cre;Ptpn2 fl/fl male mice ( Figure S2H ). Hepatic TCPTP deficiency also did not affect whole-body insulin sensitivity and glucose metabolism ( Figures S2I and S2J ). Although C57BL/6 mice fed a high fat diet become obese and steatotic, they do not develop NASH (Nakagawa et al., 2014; Wolf et al., 2014) . Strikingly 40-week high-fat-fed male Alb-Cre;Ptpn2 fl/fl mice, but not Ptpn2 fl/fl mice, developed NASH ( NASH. This included hepatocyte ballooning (Figure 2A ), a form of hepatocyte degeneration, accompanied by apoptotic and/or necrotic hepatocytes, as assessed by TUNEL staining (Figure 2B) . High-fat-fed Alb-Cre;Ptpn2 fl/fl mice also exhibited lymphocytic infiltrates as assessed by histology (Figures 2A and  2C) , another key hallmark of NASH. This included the sporadic formation of ectopic lymphoid-like structures (Pitzalis et al., 2014) , with clear T cell and B cell zones as assessed by immunohistochemistry ( Figures 2C and 2D) ; immune cell infiltrates and ectopic lymphoid-like structures were not evident in Alb-Cre;Ptpn2 fl/fl mice fed a chow diet for 40 weeks (data not shown). Ectopic lymphoid-like structures can develop at sites of inflammation and influence disease progression including cancer and have been shown to function as microniches for the formation of HCC progenitor cells in rodents and humans (Finkin et al., 2015) . Consistent with the increased immune cell infiltrates and ectopic lymphoid-like structure formation, we noted that the mRNA expression of pro-inflammatory cytokines including IL-6 (Il6), TNF (Tnf), and interferon (IFN)g (Ifng) and that of acute phase response genes, including Saa1, Saa3, and Crp, were elevated in the livers of high-fat-fed Alb-Cre;Ptpn2 fl/fl mice ( Figure 2E ). Therefore TCPTP-deficiency in the livers of high-fat-fed mice results in marked hepatic inflammation and hepatocyte ballooning, key hallmarks of NASH.
A requisite feature of NASH is the recruitment of immune cells that contribute to the inflammation and the accompanying tissue damage and repair. Accordingly, we characterized the immune cell subsets recruited to the livers of 40-week high-fat-fed Alb-Cre;Ptpn2 fl/fl mice by flow cytometry. The increase in lymphocytic infiltrates was predominated by CD4 + and CD8 + T cells that had an effector-memory phenotype (CD44 hi CD62L lo ) and expressed markers of activated T cells (CD25 hi CD69 hi ), including cytotoxic CD8 + T cells (IFNg hi TNF hi ) (Figures 2F and S3A) . We also found a small but significant increase in B cells ( Figure 2F ), but no alterations in NKT cells, NK cells, macrophages/monocytes, granulocytes, myeloid-derived suppressor cells, T helper 17 cells, or immunosuppressive IL-10 expressing CD4 + T cells and regulatory T cells ( Figures S3B-S3F ). Recent studies have shown that inflammation in NAFLD is accompanied by the accumulation of liver-resident immunoglobulin-A producing (IgA + ) cells that express programmed death ligand-1 (PD-L1) and IL-10 and suppress the anti-tumor activity of cytotoxic CD8 + T cells and thereby contribute to the formation of HCC (Shalapour et al., 2017) . We found increased IgA + cells that expressed high levels of PD-L1 in the livers of 40-week high-fat-fed Alb-Cre;Ptpn2 fl/fl mice ( Figure 2F ). However, whereas hepatic CD8 + T cells in 40-week high-fat-fed Alb-Cre;Ptpn2 fl/fl mice constituted 15% of the total lymphocyte pool, IgA + cells constituted 0.1% of the total lymphocyte pool. An expected outcome of cytotoxic T cell recruitment and activation would be tissue damage and ensuing reparative responses leading to fibrosis.
In keeping with this we found that 40-week high-fat-fed Alb-Cre;Ptpn2 fl/fl had increased liver damage, as indicated by the increased collagen deposition and fibrosis (Picro Sirius Red or Mason's trichrome staining; Figure 2G ), the increased expression of fibrotic genes, including those encoding a-smooth muscle actin (Acta2) and transforming growth factor b (Tgfb) ( Figure 2H ), and the increased levels of the liver enzymes alanine transaminase (ALT) and aspartate aminotransferase (AST) in serum ( Figure 2I ), a sign of liver damage. By contrast, high-fatfed Alb-Cre;Ptpn2 fl/fl mice crossed onto the Rag1 -/background, so that they lacked mature T cells and B cells, did not exhibit overt fibrosis ( Figures 2J and 2K ). These results are consistent with TCPTP deletion, or otherwise oxidation and inactivation, driving T cell recruitment and the progression from NAFL to NASH and fibrosis.
To further explore the impact of TCPTP-deficiency on NASH pathogenesis, Ptpn2 fl/fl versus Alb-Cre;Ptpn2 fl/fl mice were fed a choline-deficient amino acid-defined (CDAA) diet that promotes NASH and fibrosis in C57BL/6 mice without promoting obesity (Merry et al., 2016) . Hepatic TCPTP-deficiency in CDAA-fed mice did not alter body weight or adiposity ( Figure S2K ) and did not alter the development of steatosis, as assessed by (1) histology ( Figure 2L ), (2) the expression of lipogenic and fatty acid synthesis genes ( Figure 2M ), and (3) by measuring TAGs (Figure 2N ). However, TCPTP-deficiency resulted in increased lymphocytic infiltrates ( Figure 2L ), hepatic inflammation ( Figure 2O 
TCPTP Inactivation Promotes HCC in Obesity
HCC can develop in a subset of NAFLD patients, particularly in patients where persistent inflammation and reparative responses drive the development of fibrosis or cirrhosis (Font-Burgada et al., 2016; Ringelhan et al., 2018) . Such fibrotic/cirrhotic livers may contain hepatocyte-derived HCC progenitors that can undergo malignant transformation and give rise to HCC (Finkin et al., 2015; He et al., 2013) . Moreover, the development of HCC in NAFLD can also involve the recruitment of immunosuppressive cells that subvert anti-tumor immunity (Shalapour et al., 2017) . Consistent with the development of NASH and fibrosis and the increased abundance of IgA + PD-L1 hi immunosuppressive cells, 40-week high-fat-fed Alb-Cre;Ptpn2 fl/fl mice developed nodular tumors of variable size in approximately one-third of mice . Tumor formation did not occur or was evident at a low incidence in high-fat-fed Ptpn2 fl/fl control mice. Tumors were not evident in Ptpn2 fl/fl or Alb-Cre;Ptpn2 fl/fl mice fed a standard chow diet consistent with tumor formation being associated with obesity ( Figure 3A ; data not shown). The tumors that developed in high-fat-fed Alb-Cre;Ptpn2 fl/fl mice were clearly defined from the adjacent parenchyma and were (D and E) histology, (F) immunohistochemistry, or (G) immunoblotting. Representative and quantified results (means ± SEM) results are shown for the indicated number of mice (B) or cohorts (C) . See also Figure S4 . steatohepatitic ( Figure 3D ), but did not exhibit any changes in the abundance of enzymes associated with lipogenesis ( Figure S4A ). Tumors in high-fat-fed Alb-Cre;Ptpn2 fl/fl mice completely lacked any reticular structure as reflected by the absence of reticulin staining and were disorganized and multi-layered ( Figure 3E ), consistent with these being carcinomas. Tumors, but not the adjacent parenchyma, exhibited increased Ki67 staining (Figure 3F) , indicative of proliferating cells within tumor lesions, as occurs in human HCC. Further immunohistological assessment indicated that tumors were positive for EpCAM and cytokeratin 19 ( Figure 3F ), which are associated with poor prognosis and invasion in human HCC (Yamashita et al., 2008) . Tumors also expressed other markers of aggressive disease, including GRP78 ( Figure 3F ), whose expression is negatively correlated with tumor grade and positively associated with invasion (Su et al., 2010) , and phosphorylation of the mitogen-activated protein kinases (MAPKs) ERK-1 and ERK-2 (p-ERK1 and p-ERK2; Figure 3F ), which are activated in the majority of human HCCs and drive growth (Calvisi et al., 2006) . The increase in ERK-1 and ERK-2 signaling was substantiated by immunoblot analysis monitoring for p-ERK-1/2 in tumor versus tumor-adjacent tissue ( Figure 3G ); JNK MAPK signaling that is required for DEN-induced HCC in mice (Sakurai et al., 2006) was also increased ( Figure 3G ), whereas there were no overt increases in p38 MAPK ( Figure S4B ) or phosphatidylinositol 3-kinase (PI3K)-AKT signaling (Figure S4C) . As seen in human HCC, tumors in high-fat-fed Alb-Cre;Ptpn2 fl/fl mice expressed higher levels of the epidermal growth factor receptor (EGFR) PTK ( Figure 3G ). By contrast, c-MET and insulin receptor (IR) PTK levels were unaltered or decreased ( Figure S4D ). These results indicate that TCPTP-deficiency in hepatocytes drives tumor development in obesity with many of the characteristic features of aggressive HCCs seen in humans.
TCPTP Inactivation Promotes a STAT-1 and STAT-3 Molecular Phenotype in NASH
To explore the mechanisms by which TCPTP inactivation in hepatocytes might drive the development of NASH and HCC, we performed an unbiased transcriptome analysis by RNA sequencing (RNA-seq). Total RNA was isolated from the livers (excluding tumors) of 40-week high-fat-fed Ptpn2 fl/fl versus Alb-Cre;Ptpn2 fl/fl mice and used to generate libraries for sequencing on a Illumina HiSeq1500. Differential gene expression was analyzed by supervised clustering with altered pathways determined using Ingenuity pathway analysis ( Figures 4A and S5A ). Only 24 genes were differentially expressed between the genotypes, with all but two genes showing increased expression (Figure 4A) ; 6/24 genes were also assessed by real-time qPCR in an independent cohort and shown to be upregulated (Figures 4B and S5B) . Strikingly, 18 of the differentially expressed genes were bona fide or predicted targets of IFN signaling and/or transcriptional targets of STAT-1 and/or STAT-3 and were significantly upregulated ( Figure 4A ). The top-ranked upregulated gene was Cxcl9 ( Figure 4A ) a STAT-1 transcriptional target that encodes the T cell chemoattractant CXCL9 (Semba et al., 2013; Tacke et al., 2011) . Other differentially expressed genes included those encoding the acute-phase reactants SAA-1/2 and ORM2 (Figure 4A) and those encoding the IFN-g-induced guanylate-binding proteins (GBPs)-2/3/7/10 and the immunity-related GTPases TGTP1 and IGTP ( Figure 4A ). Consistent with this, Ingenuity analyses identified acute-phase response, JAK/STAT, and cytokine signaling pathways among the top-pathways altered by TCPTP-deficiency ( Figure S4A ). These findings are in keeping with the increased hepatic inflammation and T cell infiltration, NASH, and liver damage evident in high-fat-fed Alb-Cre;Ptpn2 fl/fl mice. Indeed, other differentially expressed STAT-1 and STAT-3 target genes included those encoding fibrinogen-like 1 (FGL-1) and lipocalin-2 (LCN2) ( Figures 4A and 4B ), hepatokines elevated in the livers or serum of patients with NALFD (Auguet et al., 2013; Semba et al., 2013; Tacke et al., 2011; Wu et al., 2013; Yu et al., 2009; Zhao et al., 2014) . Increased Cxcl9 gene expression was also evident in hepatocytes from chow-fed Alb-Cre;Ptpn2 fl/fl mice ( Figure 4C ) consistent with the increased Cxcl9 expression being hepatocyte cell intrinsic and potentially an early event in disease progression. By contrast Fgl1 and Lcn2 were not elevated in hepatocytes from chow-fed Alb-Cre;Ptpn2 fl/fl mice ( Figure 4C ), indicating that their expression is reliant on obesity and might reflect a later stage in disease progression. Moreover in keeping with studies showing that circulating CXCL9, FGL-1, and LCN2 levels are elevated in rodents and/or humans with NAFLD (Auguet et al., 2013; Semba et al., 2013; Tacke et al., 2011; Wu et al., 2013) , we found that CXCL9, FGL-1, and LCN2 levels were significantly increased in the sera of high-fat-fed Alb-Cre;Ptpn2 fl/fl mice ( Figure 4D ).
Our results demonstrate that TCPTP inactivation in hepatocytes can drive the STAT-1 and STAT-3-mediated expression (E) Human liver core biopsies from obese male or female patients (BMI 40-74 kg/m 2 ) were processed for histology and those with non-steatotic livers (NAS 0), simple steatosis, and no fibrosis (NAS 1-2) or overt NASH with fibrosis (NAS R 5) were identified. Representative histology micrographs. Biopsies were processed for real-time PCR. (F and G) Mice were fed an HFD for 40 weeks. Liver and tumor tissues were extracted for (F) immunoblotting or (G) immunohistochemistry. (H) Mice were fed a CDAA diet for 12 wks. Livers were extracted and processed for immunoblotting. Representative and quantified results (means ± SEM) results are shown for the indicated number of mice or human liver biopsies. See also Figure S5 and Table S1 . of genes that might play important roles in recruiting T cells, shaping the immune response and promoting the reparative responses of the liver that underpin the development of NASH and fibrosis. Accordingly, we asked whether such genes might be differentially expressed in obese humans with NAFL versus NASH. The expression of CXCL9, FGL1, and LCN2 was assessed in liver core biopsies from obese patients (BMI 36-61) with normal livers without steatosis (NAS 0) versus obese patients (BMI 36-61) with NAFL (NAS 1-2), without immune cell infiltrates or fibrosis, or in obese patients (BMI 47-74) with overt NASH (NAS R5) and fibrosis ( Figure 4E ; Table S1 ). We found that the hepatic expression of all three human genes was increased in the livers of obese patients with NAFL when compared to those with normal livers ( Figure 4E ), consistent with studies implicating such factors in human NAFLD (Tacke et al., 2011; Wu et al., 2013) . Strikingly, we found FGL1 and CXCL9 expression increased yet further in the livers of obese patients with NASH ( Figure 4E ). These findings identify FGL1 and CXCL9 as potential discriminatory factors for NASH versus NAFL. Also, these studies indicate that the molecular processes underpinning NASH in high-fat-fed Alb-Cre;Ptpn2 fl/fl mice may reflect those occurring in human patients developing NASH.
TCPTP Inactivation Promotes STAT-1-Dependent NASH As STAT-1 and STAT-3 can serve as direct nuclear substrates for TCPTP (Loh et al., 2011; ten Hoeve et al., 2002) , we assessed their phosphorylation in the livers of 40-week high-fat-fed Alb-Cre;Ptpn2 fl/fl mice ( Figure 4F ). TCPTP deletion enhanced p-STAT-1 and p-STAT-3 in tumor adjacent and tumor tissue in the livers of high-fat-fed Alb-Cre;Ptpn2 fl/fl mice ( Figure 4F ). The promotion of STAT-1 and STAT-3 signaling was cell-intrinsic, as indicated by the increased p-STAT-1 and p-STAT-3 in the nuclei of hepatocytes examined by immunohistochemistry (Figure 4G) . No overt increases were evident in the tyrosine phosphorylation and activation of PTKs that normally phosphorylate STAT-1 and STAT-3 including JAK-1, JAK-2, and Src family kinases (SFKs) (Figures S4B and S4E) indicating that TCPTP deficiency may elicit its effects at the level of STAT-1 and STAT-3. Indeed, JAK-1 phosphorylation was decreased in the livers and tumors of 40-week high-fat-fed Alb-Cre;Ptpn2 fl/fl mice (Figure S4B) and this was accompanied by increased expression of the gene encoding the JAK PTK inhibitor and STAT transcriptional target, suppressor of cytokine signaling (SOCS)-1 (Figure S4F ); the expression of other negative regulators of JAK/ STAT signaling including SOCS-3 and the tyrosine phosphatases PTP1B (Ptpn1), SHP-1 (Ptpn6), and SHP-2 (Ptpn11) was unaltered ( Figures S4F and S4G ). Nonetheless, consistent with TCPTP-deficiency increasing STAT-1 and STAT-3 signaling, we found that the exacerbation of NASH in Alb-Cre;Ptpn2 fl/fl mice fed a CDAA-diet was also accompanied by the increased tyrosine phosphorylation of STAT-1 and STAT-3 ( Figure 4H ).
To determine the extent to which the heightened hepatic STAT-1 and STAT-3 signaling might drive NASH and HCC in high-fat-fed Alb-Cre;Ptpn2 fl/fl mice, we sought to correct the enhanced STAT-1 or STAT-3 signaling. To this end, we crossed Alb-Cre;Ptpn2 fl/fl mice onto the Stat-1 fl/+ or Stat-3 fl/+ backgrounds to reduce STAT-1 or STAT-3 by 50% in hepatocytes so that hepatic p-STAT-1 and p-STAT-3 might approximate that in Ptpn2 fl/fl controls. Stat-1 fl/+ or Stat-3 fl/+ heterozygosity reduced STAT-1 and STAT-3 protein levels in liver homogenates by 50% ( Figures 5A and 6A ). Importantly, STAT-1 heterozygosity partially corrected the enhanced p-STAT-1 ( Figure 5A ), whereas STAT-3 heterozygosity completely corrected the enhanced p-STAT-3 ( Figure 6A ). Strikingly, we found that repressing p-STAT-1 corrected the hepatic inflammation, as reflected by the expression of inflammatory and acute-phase reactant genes ( Figure 5B ). Conditional Stat1 heterozygosity also corrected the enhanced hepatic expression of the STAT-1 target gene Cxcl9 (Figure 5B ), which we had identified as the top hit in our transcriptome analysis ( Figure 4A ). Stat1 heterozygosity also largely corrected the enhanced hepatic expression of STAT-1 target gene Lcn2 ( Figure 5B ). By contrast, conditional Stat1 heterozygosity did not alter the expression of Il6, Fgl1, or Ccl5 that were also elevated in the livers of high-fat-fed Alb-Cre;Ptpn2 fl/fl mice ( Figure 5B ), consistent with these being targets of STAT-3 (He et al., 2013; Kovacic et al., 2010; Yu et al., 2009) . Nonetheless, attenuating the enhanced p-STAT-1 corrected the increased immune cell recruitment ( Figures 5C  and 5D ). In particular, Stat1 heterozygosity corrected the increased recruitment of effector-memory CD4 + and CD8 + T cells expressing markers of activated and/or cytotoxic T cells ( Figure 5D ). Moreover, Stat1 heterozygosity corrected the increased fibrosis ( Figures 5B and 5C ). By contrast, correcting the enhanced STAT-3 signaling resulting from TCPTP-deletion in hepatocytes reduced the expression of the STAT-3 target genes Il6, Ccl5, and Fgl1 ( Figure 6B ) and reduced the expression of Ifng, Tnf, and Saa1 ( Figure 6B ). However, Stat3 heterozygosity neither altered the expression of Cxcl9 or Lcn2 (Figure 6B ), nor did it attenuate the accumulation of activated T cells (Figures 6C and 6D) or fibrosis ( Figures 6B and 6C) . These results indicate that although both the enhanced STAT-1 and STAT-3 signaling accompanying TCPTP deletion in hepatocytes contribute to inflammation, it is the enhanced STAT-1 signaling that is responsible for the T cell accumulation and the development of NASH and fibrosis in high-fat-fed Alb-Cre;Ptpn2 fl/fl mice. hepatocytes repressed the accumulation of activated T cells and prevented inflammation and fibrosis, it did not prevent tumors forming in high-fat-fed Alb-Cre;Ptpn2 fl/fl mice ( Figure 7A ). These results indicate that tumor development in high-fat-fed Alb-Cre;Ptpn2 fl/fl mice occurs independently of NASH and fibrosis. To explore the mechanisms that drive HCC in high-fat fed Alb-Cre;Ptpn2 fl/fl mice, we turned our attention on STAT-3. STAT-3 is frequently activated in human HCC and is essential for HCC in DEN-treated mice . Accordingly, we assessed whether STAT-3 heterozygosity might suppress the development of HCC in high-fat-fed Alb-Cre;Ptpn2 fl/fl mice. Although Stat3 heterozygosity in hepatocytes did not influence the recruitment of activated effector T cells and the development of fibrosis ( Figures 6C and 6D) , it completely repressed the increased tumor incidence ( Figure 7B ). These results point toward TCPTP-deficiency and the promotion of STAT-3 signaling driving the development of HCC in obesity.
To further explore whether the enhanced p-STAT-3 in obese Alb-Cre;Ptpn2 fl/fl mice might promote tumorigenicity independently of NASH and fibrosis, we assessed the impact of TCPTP-deficiency in hepatocytes on the development of HCC in mice treated with the chemical carcinogen diethylnitrosamine (DEN). DEN promotes the development of liver tumors in mice with many of the key characteristics of HCC in humans (Maeda et al., 2005) . However, although DEN-induced tumorigenicity is dependent on inflammation and IL-6 and/or STAT-3 signaling Park et al., 2010) , tumors develop in the absence of NASH or fibrosis (Park et al., 2010) . We found that TCPTP deletion in hepatocytes promoted the development of HCCs in DEN-treated mice ( Figure S6A ). The increased tumorigenicity resulting from TCPTP-deficiency was accompanied by an increase in p-STAT-3 in tumor and non-tumor tissue alike (Figures S6B  and S6C ). Tumors were highly proliferative as noted by an increase in Ki67 staining ( Figure S6D ) and an increase in EGFR and cyclin D1 protein and gene expression ( Figures S6E  and S6F ). Tumors also exhibited increased markers of glycolytic metabolism, including increased expression of the gene encoding HIF-1a ( Figure S6F ), a transcriptional target of STAT-3 that can promote glycolysis by driving GLUT1, PDK1, and PKM2 expression (Demaria and Poli, 2012) . Consistent with the increase in Hif1a, we found that Glut1, Pdk1, and PKM2 levels were also elevated in TCPTP-deficient tumors ( Figures  S6E and S6F) . Importantly, we found that conditional Stat3 heterozygosity in Alb-Cre;Ptpn2 fl/fl mice ( Figure 7C ) completely repressed the enhanced tumorigenicity otherwise associated with TCPTP deficiency (Figures 7D-7F) and corrected the increased expression of genes associated with cellular proliferation and glycolysis ( Figures 7G and 7H) . These findings provide causal evidence for TCPTP inactivation in hepatocytes driving HCC in a STAT-3-dependent manner and substantiate the assertion that the inactivation of hepatic TCPTP in obesity may drive HCC independent of NASH and fibrosis.
TCPTP Deletion in HCC Cells Promotes Tumorigenicity TCPTP inactivation might not only contribute to the transformation of progenitors and development of HCC in obesity, but also elicit cell autonomous effects on the growth of HCC once established. To explore this, we isolated HCC cells from DEN-induced tumors in Ptpn2 fl/fl mice ( Figure S7A ). Ptpn2 fl/fl HCC cells were transduced with retroviruses expressing GFP, or GFP and Cre, and sorted to generate isogenic HCC cell lines with or without TCPTP ( Figure S7B ). TCPTP was deleted in two Ptpn2 fl/fl HCC cell lines expressing Cre recombinase and this was accompanied by the promotion of basal and IL-6-induced STAT-3 signaling ( Figures S7B and S7C ; data not shown); TCPTP-deficiency also increased p-STAT-3 in HCC cell lines derived from tumors arising in DEN-treated Alb-Cre;Ptpn2 fl/fl versus Ptpn2 fl/fl mice ( Figure S7D ). TCPTP deletion did not alter PI3K-AKT or ERK-1 and ERK-2 signaling ( Figure S7C ) or cellular proliferation, migration, or anoikis (data not shown), but significantly increased anchorage-independent growth in soft agar ( Figure 7I ). The increased growth in soft agar was accompanied by the increased expression of STAT-3-target genes encoding c-Myc and cyclin D1 ( Figure 7J ) that drive tumor growth. Finally, we found that TCPTP-deficiency in HCC cells increased tumor xenograft growth in nude mice ( Figure 7K ) accompanied by increased p-STAT-3 and proliferation as assessed by Ki67 staining (Figure 7L ). Taken together, these results point toward TCPTP inactivation in HCC cells eliciting cell autonomous effects on HCC growth.
DISCUSSION
The incidence of overweight and obese individuals and the accompanying development of type 2 diabetes and the metabolic syndrome have ballooned to epidemic proportions. The obesity and type 2 diabetes epidemics are major drivers of NAFLD (Font-Burgada et al., 2016) . Patients with NAFLD are at risk of developing HCC and this typically occurs in the setting of NASH and advanced fibrosis or cirrhosis (Font-Burgada et al., 2016) . This coincidence has yielded the widely held belief that HCC in NAFLD must be predicated by the development of NASH with advanced fibrosis or cirrhosis. Indeed, American and European surveillance programs for HCC have been limited to those individuals with cirrhosis. However, in the last few years, it has become apparent that in roughly half of all cases where HCC develops in the context of NASH, this is evident before the onset of cirrhosis (Alexander et al., 2013; Mittal et al., 2015; Paradis et al., 2009; Rahman et al., 2013; Takuma and Nouso, 2010; Younes and Bugianesi, 2018) . Indeed, in patients with metabolic syndrome, HCC might even occur in the context of simple steatosis in the absence of any NASH and inflammation or fibrosis (Alexander et al., 2013; Baffy et al., 2012) . The mechanisms that contribute to the development of HCC in NAFLD in the absence of NASH and/or overt fibrosis or cirrhosis have remained unexplored. Our studies indicate that development of NASH and fibrosis versus HCC in obesity can be independent events, driven by the respective engagement of hepatocyte STAT-1 and STAT-3 transcriptional programs that promote T cell recruitment and liver damage versus tumorigenicity.
In this study we have shown that STAT-1 signaling is progressively elevated in the livers of mice fed NAFL-versus NASH-promoting diets and increased in the livers of obese patients with NAFLD. Moreover, we have shown that the STAT-1 phosphatase TCPTP (ten Hoeve et al., 2002) is oxidized in the livers of obese mice with NAFL or NASH and obese humans with NAFLD. Furthermore, the deletion of TCPTP increased STAT-1 signaling in hepatocytes to promote T cell accumulation, inflammation, NASH, and fibrosis in C57BL/6 mice fed a high fat diet that normally develop steatosis, but not NASH and fibrosis (Park et al., 2010) . RNA-seq analyses demonstrated that known and/or putative hepatic STAT-1 and STAT-3 target genes were elevated in the livers of high-fat-fed obese TCPTP-deficient mice. Although some of the elevated hepatic STAT-1 and STAT-3 target genes might reflect contributions from infiltrating immune cells, the expression of the STAT-1 target gene Cxcl9 was hepatocyte intrinsic, whereas the STAT-3 target genes Il6, Fgl1, and Ccl5 were elevated independently of NASH and T cell recruitment. Cxcl9 is produced by parenchymal and non-parenchymal cells and is elevated in the Shionogi mouse model, an inbred mouse strain that spontaneously develops NASH and HCC (Semba et al., 2013) . Cxcl9 expression is also elevated in humans with NAFLD and correlates with worsening fibrosis (Wasmuth et al., 2009) . Similarly Lcn2 is highly expressed by myeloid cells and hepatocytes, especially under conditions of stress, and may recruit immune cells such as neutrophils to sites of injury and inflammation (Li et al., 2018) . Increased circulating LCN-2 has been reported in human NALFD (Auguet et al., 2013) and may contribute to NAFLD pathogenesis (Ye et al., 2016) . Our studies are consistent with a STAT-1 gene signature being of functional relevance to the development of NASH. However, whether the promotion of STAT-1 signaling occurs solely as a consequence of the oxidation and inactivation of TCPTP, or whether this involves the oxidation of other phosphatases that antagonize JAK/STAT signaling, or indeed even alternate mechanisms, remains to be resolved.
We found that several STAT-3 target genes were also elevated in the livers of high-fat-fed liver-TCPTP-deficient mice. These included Fgl1, a hepatocyte-derived factor whose circulating levels are increased in human NAFLD and acute phase reactant genes. Although such STAT-3 target genes may contribute to inflammatory processes in NAFLD, they were not essential for the T cell recruitment or activation, nor the development of fibrosis. Irrespective, consistent with STAT-1 and STAT-3 signaling being important in NAFLD pathogenesis, we found that the STAT-1 and STAT-3 targets genes Cxcl9, Lcn2, and Fgl1 were also elevated in the livers of obese humans with NAFL when compared to those without steatosis. Notably, CXCL9 and FGL1 were increased yet further in the livers of obese humans with NASH and fibrosis. These findings reaffirm the importance of STAT-1 and STAT-3 signaling in NAFLD pathogenesis and substantiate our mouse model as one that appropriately reflects the NAFL to NASH and fibrosis transition in humans.
Strikingly, our studies indicate that the recruitment of T cells and the development of NASH and fibrosis per se are not essential for the development of HCC in obesity. Although STAT-1 heterozygosity in hepatocytes in high-fat-fed liver-TCPTP-deficient mice corrected the recruitment of T cells and prevented fibrosis, it did not prevent tumor formation. Rather, obesity and the enhancement of STAT-3 signaling were instrumental in driving HCC, as tumors were not evident in chow-fed mice and tumor development in high-fat-fed mice was prevented when the increased STAT-3 signaling was corrected. STAT-3 is activated in nearly 60% of HCCs that arise in the context alcoholic-and hepatitis B/C-driven cirrhosis (Calvisi et al., 2006; He et al., 2010) and is essential for DEN-induced HCC in rodents Naugler et al., 2007) . Hepatocyte STAT-3 signaling is also essential for the exacerbation of DEN-induced HCC by obesity (Park et al., 2010) , whereas an IL-6-STAT-3 autocrine loop is required for the malignant progression of HCC progenitors in high-fat-fed MUP-Upa mice (He et al., 2013) . We found that Il6 expression was increased in the livers of high-fat-fed liver-TCPTP-deficient mice and this was corrected by STAT-3 heterozygosity. Therefore, TCPTP inactivation in obesity may promote the development of HCC by increasing STAT-3 signaling and exacerbating an IL-6-STAT-3 autocrine loop to drive the transformation of HCC progenitors. These results are consistent with others implicating TCPTP as a tumor suppressor (Kleppe et al., 2010; Shields et al., 2013) .
The results of this study point toward the promotion of STAT-3 signaling being sufficient to drive tumor development in obesity and NAFLD independently of NASH and fibrosis. Our findings argue for the oxidative and inflammatory environments in NAFLD being principally important in the promotion of tumorigenesis, rather than NASH and fibrosis per se. Our results shed light on the mechanisms that may be contributing to the growing incidence of HCC in NAFLD patients without advanced fibrosis or Figures S6 and S7. cirrhosis, a phenomenon likely to rise with the growing incidence of obesity and type 2 diabetes and the alarming rise in childhood obesity and NAFLD.
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METHODS DETAILS
IL-6 signaling
For IL-6 stimulation assays HCC cells were serum-starved in DMEM containing 0.1% (v/v) FBS for 6 h and stimulated with 1 ng/ml murine recombinant IL-6 (Peprotech, Rehovot, Israel) for the indicated times and processed for immunoblotting as described previously (Shields et al., 2013) .
Immunofluorescence microscopy
For immunofluorescence microscopy, cells grown on glass coverslips were fixed in 3.2% (w/v) paraformaldehyde and processed as described previously (Loh et al., 2011) .
Metabolic and blood measurements
Mouse body weights were monitored weekly and body composition was assessed by dual-energy X-ray absorptiometry (DEXA; Lunar PIXImus2, GE Healthcare). Insulin and glucose tolerance tests were performed as described previously (Loh et al., 2009 ). Blood was collected from the retro-orbital sinus and fed (9 am) and fasted (12 h overnight fast) plasma insulin levels determined using a Rat insulin RIA kit (Merck Millipore, CA) and the corresponding blood glucose levels determined with an Accu-Check glucometer. Fed serum ALT and AST levels were determined using the Transaminase CII kit from Wako Pure Chemical Industries (Osaka, Japan) as described previously (v/v) glycerol, 1.5 mM MgCl2, 1 mM EGTA, 50 mM NaF, leupeptin (5 mg/ml), pepstatin A (1 mg/ml), 1 mM benzamadine, 2 mM phenylmethysulfonyl fluoride, 1 mM sodium vanadate) and clarified by centrifugation at 50,000 g for 20 min at 4 C. Clarified tissue/tumor homogenates were resolved by SDS-PAGE and transferred to PVDF and immunoblotted. For analysis of total PTP oxidation livers were processed as described previously and oxidized PTPs detected by immunoblotting using the PTPox antibody that detects virtually all classical tyrosine-specific PTPs when their catalytic Cys residues are oxidized to the -SO 3 H state (Karisch et al., 2011) . Briefly, liver samples were mechanically homogenized under anaerobic conditions in degassed, ice-cold PTPox lysis buffer (20 mM HEPES pH 6.5, 150 mM NaCl, 10% glycerol, 1%NP40, 20 mM NaF) containing 10 mM N-ethylmaleimide and incubated for 1 hr at 4 C to prevent any post-lysis Cys oxidation and to alkylate any reduced and active PTPs. Homogenates were then clarified by centrifugation (50,000 g, 20 min at 4 C) and the buffer exchanged (NAP-5 columns, GE Healthcare) into 20 mM HEPES containing 10 mM DTT to reduce oxidized Cys before further buffer exchange into 20 mM HEPES containing 100 mM pervanadate to hyper-oxidise reduced PTPs to the -SO 3 H state for analysis by SDS-PAGE and PTPox immunoblotting.
Liver TAGs, DAGs and ceramide were extracted and quantified as described previously (Loh et al., 2009) Histology and immunohistochemistry Livers and tumor tissues were fixed overnight in a neutral-buffered formalin solution and then transferred to 70% ethanol. Tissue processing and embedding were performed by the Monash Histology Platform (Monash University, Clayton Campus, Australia) and sections were stained with Hematoxylin-Eosin, PicoSirius Red or Mason's Trichrome using standard procedures. Immunohistochemistry was performed using the EnVision detection system (Dako; Agilent Technologies; Santa Clara, CA, USA) as per the manufacturer's instructions with modifications. Briefly, sections were de-paraffinised with xylene and rehydrated with three successive changes in ethanol. Heat-induced epitope retrieval was performed by placing slides in a pressure cooker at 120 C for 9 min with sections immersed in Tris-EDTA (pH 8.0) followed by endogenous peroxidase blocking (Dako REAL Peroxidase-Blocking Solution). Nonspecific antibody binding was blocked with 1% (w/v) BSA and primary antibodies were incubated at 4 C in a humidified chamber overnight. The appropriate horseradish peroxidase (HRP)-conjugated secondary antibody polymer was incubated for 1 h at room temperature. Immunoreactivity was visualized by diaminobenzidine tetrahydrochloride staining. Slides were counterstained with hematoxylin, dehydrated and mounted in a slide-mounting medium (Permount, Thermo Fisher Scientific, Carlsbad, CA, USA). Primary antibodies used for immunohistochemistry are listed in the resources table. Image acquisition was performed using an Aperio Scanscope AT Turbo slide scanner with 40x magnification and 0.25 mm/pixel resolution. Quantification of positive staining per mm 2 was performed using an automated cell counter script in Aperio ImageScope (Aperio Technologies, Vista, CA, USA).
NASH scoring
The NAFLD Activity Score, the unweighted sum of the steatosis (0-3), lobular inflammation (0-3) and hepatocellular ballooning (0-2) scores, and the fibrosis score (0-4) according to the Kleiner classication were determined for liver biopsies from obese patients.
Xenograft and soft agar assays HCC cells were processed for soft-agar assays as described previously (Shields et al., 2013) . Xenograft studies were performed as described previously (Shields et al., 2013) . Briefly HCC cells were detached with 10 mM EDTA-PBS and 1x10 6 cells resuspended in 100 ml in a 1:1 mixture of PBS and growth factor-reduced Matrigel (BD Biosciences) and injected subcutaneously into the flanks of male BALB/c nu/nu mice under isoflurane anesthesia [2% (v/v) isoflurane in 250 mL/min oxygen]. Palpable tumors were measured twice weekly using digital calipers (tumor volume = length x width 2 /2) and growth curves (up to 1000 mm 3 ) determined. Tumors were dissected and weighted and processed for immunohistochemistry or biochemical analyses.
Flow cytometry
Hepatic lymphocytes were isolated from liver tissue and mashed through a wire mesh (200 micron pore size). Hepatocytes and cell debris were removed by Percoll 33.75% (v/v) (GE Healthcare) gradient centrifugation at room temperature. Contaminating red blood cells were lysed using a 0.17 M hypotonic ammonium chloride buffer (Red Blood Cell Lysing Solution, Sigma-Aldrich). For surface staining, cells (1x10 6 /10 ml) were resuspended in D-PBS supplemented with 2% (v/v) FBS containing the antibody cocktail in 96-well microtiter plates (Falcon, BD Biosciences) for 20 min on ice in the dark and analyzed using a LSRII or Fortessa or Symphony (BD Biosciences). For detection of intracellular FoxP3 the Foxp3/Transcription Factor Staining Buffer Set (eBioscience) was used according to the manufacturer's instructions. For the detection of intracellular cytokines, lymphocytes were stimulated with ionomycin (1 mg/ml) and PMA (20 ng/ml) in the presence of Golgi Stop and Golgi Plug (BD Biosciences) for 4 h in complete T cell medium at 37 C. Cells were harvested, fixed and permeablized with the BD Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer's instructions. Cells were stained with the specified antibodies at room temperature for 30 min and processed for flow cytometry.
The following antibodies from BD Biosciences (San Jose, CA) or BioLegend (San Diego, CA) or eBioscience (San Diego, CA) were used for flow cytometry: Fluorescein isothiocyanate (FITC)-conjugated CD44 (IM7), Pacific Blue (PB)-conjugated CD69 (H1.2F3), phycoerythrin (PE)-conjugated CD3 (145-2C11), allophycocyanin (APC)-Cy7-conjugated TCR-b (H57-597), phycoerythrin-cyanine 7 (PE-Cy7)-conjugated CD4 (RM4-5), PB-or allophycocyanin (APC)-conjugated CD8 (53-6.7), Alexa 647-conjugated CD11c (N418), FITC-conjugated CD11b (M1/70), PE-conjugated Ly-6G/Ly-6C (RB6-8C5), PE-conjugated Ly-6G (1A8), APC-Cy7-conjugated Ly6C (AL-21), PE-Cy7-conjugated I-A/I-E (M5/114.115.2), APC-conjugated F4/80 (BM8), PE-conjugated NK1.1 (PK136), APC-Cy7-conjugated B220 (RA3-6B2), PE-Cy7-conjugated CD19 (1D3), PE-or APC-Cy7-conjugated CD25 (PC61), APC-conjugated CD62L (MEL-14), APC-conjugated CD138 (281-2), biotinylated CD274 (MIH5), FITC-conjugated IgA (mA-6E1), PE-or BD Horizon BV421-conjugated IL-17A (TC11-18H10), PE-conjugated IL-10 (JES5-16E3), PE-or PE-Cy7-conjugated IFN-g (XMG1.2), APC-or BD Horizon BV421-conjugated TNF (MP6-XT22), V450-conjugated FoxP3 (MF23). PerCP-Cy5.5-or BD Horizon V500-conjugated Streptavidin was used to detect cells stained with biotinylated antibodies. APC-labeled, a-galactosylceramide (aGalCer)loaded CD1 tetramers were a gift of Dale I. Godfrey (Peter Doherty Institute, Melbourne, Australia).
Quantitative PCR
RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA, USA) or RNAZol (Sigma-Aldrich, ST Louis, MO) and RNA quality and quantity was determined using a NanoDrop 3300 (Thermo Scientific, Wilmington, DE, USA) and by gel electrophoresis. mRNA was reverse transcribed using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) and processed for quantitative real-time PCR using the TaqMan Universal PCR Master Mix and TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA) (Table S2 ). Reactions were run in technical duplicate on a CFX384 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Gene expression was normalized to Gapdh or Rn18s (mouse) or 18 s (human). Relative quantification was achieved using the DDCT method.
Table S2. TaqMan Gene Expression Assays
Fasn Mm00662319_m1
Srebp-f1 Mm00550338_m1
Pparg Mm00440940_m1 Cd36 Mm00432403_m1
Scd1 Mm00772290_m1
Igf1 Mm00439560_m1 Il6 Mm00446190_m1 Tnf Mm00443258_m1
Ifng Mm01168134_m1
Cxcl9 Mm00434946_m1
CXCL9 Hs00171065_m1
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Transcriptome analysis
Mouse liver transcriptome analysis was performed using Agilent SureSelect Strand Specific RNA Library Preparation Kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. Briefly, RNA was isolated using TRIzol and quantity and integrity of RNA was analyzed using an RNA 6000 Pico LabChip on an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). 3 mg of RNA from each sample was used to prepare the sequencing library through fragmentation of the RNA followed by first-and second-strand synthesis of cDNA. After adenylation of the cDNA 3 0 end sequencing adaptors were ligated and the adaptor-ligated cDNA amplified with indexing primers by PCR (37 C for 15 min, 95 C for 2 min followed by 11 cycles of 95 C for 30 s, 65 C for 30 s and 72 C for 1 min and a final extension at 72 C for 5 min). Purified cDNA libraries were analyzed for sample integrity and quantity using a high sensitivity DNA chip on an Agilent Bioanalyzer 2100. RNA sequencing was performed on an Illumina HiSeq1500 (with a 50-base single-end read mode; > 7 3 10 6 reads) sequencing platform at the Kazusa DNA Research Institute (Kisarazu, Chiba, Japan). Raw sequencing reads were trimmed for adaptor contamination using Cutadapt (adaptor sequence AGATCGGAAGAGC; minimum overlap 3 nucleotides; maximum mismatches 10%) and for base-call quality with Trimmomatic, before being mapped to the mouse genome, including annotated or novel splice junctions, using STAR. Uniquely mapped reads were assigned to genes using HTSeq to produce gene-wise read-counts for each sample. Genes having less than 10 reads in all samples were filtered out, then EdgeR was used to identify expressed RNAs that were differentially abundant between Ptpn2 fl/fl and Alb-Cre;Ptpn2 fl/fl mice fed a HFD for 40 weeks, normalizing for library size by the Trimmed Mean of M-values method. Relationships between regulated genes and functional groups of genes were searched for using the Ingenuity Pathway Analysis (IPA) software and knowledgebase (QIAgen Bioinformatics, Redwood City, CA).
QUANTIFICATION AND STATISTICAL ANALYSIS
All data are expressed as the mean ± the standard error of the mean (SEM). All statistical tests were performed in GraphPad Prism 7.
For all experiments where comparisons were made for more than two populations, statistically significance was assessed by Table S2 . Continued
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Gapdh Mm99999915_g1 e8 Cell 175, 1-18.e1-e9, November 29, 2018 (legend on next page) Figure S7 . TCPTP Deletion in HCC Cells Promotes STAT3 Signaling, Related to Figure 7 (A-C) Tumors from DEN-treated Ptpn2 fl/fl mice were dissociated and HCC cell lines established. (A) Ptpn2 fl/fl HCC cells, primary hepatocytes from chow-fed C57BL/6 mice and MCF10A immortalized mammary epithelial cells were processed for immunofluorescence microscopy monitoring for the presence of the hepatocyte marker albumin, or the liver cancer marker a-fetoprotein. Ptpn2 fl/fl HCC cells were transduced with retroviruses encoding GFP alone (MSCV-GFP) or GFP and Cre recombinase (MSCV-GFP-CRE) and sorted twice for GFP and either processed for (B) immunofluorescence microscopy monitoring for GFP and TCPTP, or (C) serum starved and stimulated with IL-6 (1 ng/ml) and then processed for immunoblotting monitoring for STAT-3 signaling. Quantified results (means ± SEM) are shown for the indicated number of experiments with significance determined using a Student's t test. (D) Tumors from DEN-treated Ptpn2 fl/fl or Alb-Cre;Ptpn2 fl/fl were dissociated and HCC cell lines established. HCC cells were serum starved and processed for immunoblotting.
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